ACT Announces First Patients Enrolled In Two Clinical Trials Using Embryonic Stem Cells To Treat Stargardt’s Disease And Dry Age-Related Macular Degeneration
Advanced Cell Technology, Inc. , a leader in the field of regenerative medicine, announced today the enrollment of the first patients in its two Phase 1/2 clinical trials for Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (Dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The patients were enrolled at the Jules Stein Eye Institute at the University of California, Los Angeles (UCLA).